UK markets closed

Roche Holding AG (RHHBY)

OTC Markets OTCQX - OTC Markets OTCQX Delayed price. Currency in USD
Add to watchlist
39.27-0.05 (-0.13%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close39.32
Open39.23
Bid39.31 x 40000
Ask39.32 x 40000
Day's range39.11 - 39.36
52-week range29.20 - 39.68
Volume255,700
Avg. volume2,630,524
Market cap254.466B
Beta (5Y monthly)0.13
PE ratio (TTM)19.34
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.35 (3.44%)
Ex-dividend date14 Mar 2024
1y target estN/A
  • Business Wire

    New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

    SOUTH SAN FRANCISCO, Calif., July 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes. Susvimo is the first and only refillable eye implant that provides continuous delivery of a custom

  • Globe Newswire

    New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

    Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were consistent with the known safety profile for Susvimo in people with DME and DRAdditionally, the US FDA has accepted the filing application for Susvimo in DME and DR based on one-year Pagoda and Pavilion study dataSusvimo is a unique therapeutic approach that provides continuous delivery of medicine to the e

  • Business Wire

    Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

    SOUTH SAN FRANCISCO, Calif., July 17, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo® (faricimab-svoa) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years. Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair sigh